Y Intercept Hong Kong Ltd Invests $2 Million in Organon & Co. $OGN

Y Intercept Hong Kong Ltd acquired a new stake in shares of Organon & Co. (NYSE:OGN) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 187,253 shares of the company’s stock, valued at approximately $2,000,000. Y Intercept Hong Kong Ltd owned 0.07% of Organon & Co. at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of OGN. Norges Bank purchased a new position in shares of Organon & Co. during the 2nd quarter valued at about $19,778,000. AQR Capital Management LLC lifted its holdings in Organon & Co. by 136.1% during the second quarter. AQR Capital Management LLC now owns 3,254,884 shares of the company’s stock valued at $31,507,000 after purchasing an additional 1,876,264 shares in the last quarter. Private Management Group Inc. boosted its position in shares of Organon & Co. by 46.4% in the second quarter. Private Management Group Inc. now owns 3,135,960 shares of the company’s stock worth $30,356,000 after purchasing an additional 993,950 shares during the period. Brandywine Global Investment Management LLC increased its stake in shares of Organon & Co. by 58.7% in the second quarter. Brandywine Global Investment Management LLC now owns 2,262,626 shares of the company’s stock worth $21,902,000 after purchasing an additional 837,201 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its stake in shares of Organon & Co. by 126.4% in the first quarter. Goldman Sachs Group Inc. now owns 1,435,198 shares of the company’s stock worth $21,370,000 after purchasing an additional 801,307 shares in the last quarter. 77.43% of the stock is owned by institutional investors.

Organon & Co. Stock Performance

NYSE:OGN opened at $8.88 on Thursday. The company has a debt-to-equity ratio of 9.69, a quick ratio of 1.20 and a current ratio of 1.75. Organon & Co. has a fifty-two week low of $6.18 and a fifty-two week high of $17.23. The firm has a market cap of $2.31 billion, a PE ratio of 4.62, a price-to-earnings-growth ratio of 1.87 and a beta of 0.58. The business has a 50 day moving average price of $7.75 and a 200-day moving average price of $8.74.

Organon & Co. (NYSE:OGN) last released its quarterly earnings data on Monday, November 10th. The company reported $1.01 earnings per share for the quarter, topping the consensus estimate of $0.93 by $0.08. Organon & Co. had a return on equity of 143.47% and a net margin of 7.95%.The business had revenue of $1.60 billion during the quarter, compared to analysts’ expectations of $1.57 billion. During the same quarter last year, the business posted $1.38 EPS. Equities research analysts predict that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, December 11th. Shareholders of record on Thursday, November 20th were issued a $0.02 dividend. The ex-dividend date was Thursday, November 20th. This represents a $0.08 annualized dividend and a yield of 0.9%. Organon & Co.’s dividend payout ratio (DPR) is 4.17%.

Analysts Set New Price Targets

OGN has been the topic of a number of analyst reports. Wall Street Zen upgraded shares of Organon & Co. from a “hold” rating to a “buy” rating in a research note on Saturday, January 3rd. Morgan Stanley lowered their price objective on Organon & Co. from $10.00 to $9.00 and set an “equal weight” rating on the stock in a research report on Tuesday, November 11th. JPMorgan Chase & Co. cut their target price on Organon & Co. from $14.00 to $12.00 and set an “underweight” rating for the company in a research report on Tuesday, November 11th. Barclays started coverage on Organon & Co. in a research note on Tuesday, December 9th. They set an “underweight” rating and a $7.50 target price on the stock. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Organon & Co. in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and four have issued a Sell rating to the stock. According to data from MarketBeat, Organon & Co. currently has a consensus rating of “Reduce” and a consensus target price of $8.38.

Organon & Co. Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.